Table of Contents for Supplementary Appendix

1.	TABLE S1: CLINICAL SITES AND PRINCIPAL INVESTIGATORS 3
2.	AUTHOR CONTRIBUTIONS
3.	TABLE S2: CRITERIA FOR HA INDICATION 6
4.	TABLE S3: RESPONSIBLE PERSONS FOR THE CONCEPTION OF TREATMENTS 7
5.	TABLE S4: REPRESENTATIVENESS OF STUDY PARTICIPANTS 8
6.	TABLE S5: EXCLUDED PATIENTS FROM STUDY PARTICIPATION 9
7. TRE	TABLE S6: QUANTITY AND REASONS OF DROP-OUTS BEFORE TREATMENT START PERATMENT ARM
8. TRE	TABLE S7: QUANTITY AND REASONS OF DROP-OUTS DURING TREATMENT PERATMENT ARM – BEFORE INTERIM VISIT
9. TRE	TABLE S8: QUANTITY AND REASONS OF DROP-OUTS DURING TREATMENT PERATMENT ARM – AFTER INTERIM VISIT
10.	TABLE S9: QUANTITY AND REASONS OF PATIENTS LOST TO FOLLOW-UP
11. PRO	FIGURE S1: EXTENDED PATIENTS FLOWCHART (INTENTION-TO-TREAT AND PER- TOCOL SAMPLE)
12. BAS	TABLE S10: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PARTICIPANTS ATELINE (STRATIFIED BY TREATMENT ARM).15
<i>13</i> .	TABLE S11: QUANTITY AND TYPE OF ADVERSE EVENTS PER TREATMENT ARM
14.	FIGURE S2: BOX-AND-WHISKER PLOT OF OBSERVED AND IMPUTED THI VALUES
15. FOR	FIGURE S3: AUDIOGRAM IN PATIENTS WITH AND WITHOUT HEARING AID INDICATION SINGLE AND COMBINED TREATMENT GROUPS19
16.	FIGURE S4: AUDIOGRAM FOR PATIENTS IN ALL TREATMENT GROUPS
17.	TABLE S12: PRIMARY OUTCOME (THI) OBJECTIVE 1: MODEL PARAMETERS
18. INDI	TABLE S13: THI CHANGE FROM BASELINE TO FINAL VISIT FOR HEARING AIDICATION (YES/NO)
19. TINI	TABLE S14: THI CHANGE FROM BASELINE TO FINAL VISIT FOR HIGH AND LOWNITUS DISTRESS SEVERITY23
20.	FIGURE S5: PRIMARY OUTCOME (THI) OBJECTIVE 1: MODEL ASSUMPTIONS 24
<i>21</i> .	FIGURE S6: PRIMARY OUTCOME (THI) OBJECTIVE 2
22. (BAS	TABLE S15: PRIMARY OUTCOME (THI) OBJECTIVE 2: POST-HOC COMPARISONSSELINE TO FINAL VISIT)
23.	TABLE S16: PRIMARY OUTCOME (THI) OBJECTIVE 4 & 5 AT FINAL VISIT
24.	TABLE S17: PRIMARY OUTCOME (THI) AT INTERIM VISIT 29
25.	TABLE S18: PRIMARY OUTCOME (THI) AT FOLLOW-UP
26.	TABLE S19: SECONDARY OUTCOME (TFI) OBJECTIVE 4 & 5 AT FINAL VISIT
27.	TABLE S20: SECONDARY OUTCOME (MINI-TQ) OBJECTIVE 4 & 5 AT FINAL VISIT
28. AT P	TABLE S21: SECONDARY OUTCOME (NRS-2: "HOW STRONG OR LOUD IS YOUR TINNITUSPRESENT?") OBJECTIVE 4 & 5 AT FINAL VISIT

<i>29</i> .	TABLE S22: SECONDARY OUTCOME (PHQ-9) OBJECTIVE 4 & 5 AT FINAL VISIT
30. (OB.	FIGURE S7: SECONDARY OUTCOME (CGI-I) AT FINAL VISIT – SINGLE VS. COMBINATION IECTIVE 1)
31. (OB.	FIGURE S8: SECONDARY OUTCOME (CGI-I) AT FINAL VISIT – ALL TREATMENT ARMS IECTIVE 2)
32. (OB.	FIGURE S9: SECONDARY OUTCOME (CGI-I) AT FINAL VISIT – ALL TREATMENT ARMS IECTIVE 2) IN PATIENTS WITH AND WITHOUT HEARING AID INDICATION
33. (OB.	FIGURE S10: SECONDARY OUTCOME (CGI-I) AT FINAL VISIT – ALL TREATMENT ARMS IECTIVE 2) IN PATIENTS WITH HIGH AND LOW TINNITUS DISTRESS SEVERITY
<i>34</i> .	TABLE S23: SECONDARY OUTCOME (WHO-QOL-BREF 1: PHYSICAL HEALTH) AT FINAL 39
VISI	<i>T</i>
35. FIN	TABLE S24: SECONDARY OUTCOME (WHO-QOL-BREF 2: PSYCHOLOGICAL HEALTH) ATAL VISIT
36.	TABLE S25: SECONDARY OUTCOME (WHO-QOL-BREF 3: SOCIAL FACTORS) AT FINAL 41
VISI	<i>T</i>
37.	TABLE S26: SECONDARY OUTCOME (WHO-QOL-BREF 4: ENVIRONMENT) AT FINAL
VISI	<i>T</i>
38. TIN	TABLE S27: SECONDARY OUTCOME (NRS 1: "HOW MUCH OF A PROBLEM IS YOURNITUS AT PRESENT?") AT FINAL VISIT
39. AT F	TABLE S28: SECONDARY OUTCOME (NRS 3: "HOW UNCOMFORTABLE IS YOUR TINNITUSPRESENT?") AT FINAL VISIT
40. PRE	TABLE S29: SECONDARY OUTCOME (NRS 4: "HOW ANNOYING IS YOUR TINNITUS ATSENT?") AT FINAL VISIT
41. TIN	TABLE S30: SECONDARY OUTCOME (NRS 5: "HOW EASY IS IT FOR YOU TO IGNORE YOURNITUS AT PRESENT?") AT FINAL VISIT
42. PRE	TABLE S31: SECONDARY OUTCOME (NRS 6: "HOW UNPLEASANT IS YOUR TINNITUS ATSENT?") AT FINAL VISIT
<i>43</i> .	FIGURE S11: PER PROTOCOL (N = 185) PRIMARY OUTCOME (THI)
44.	TABLE S32: PER PROTOCOL (N = 185) PRIMARY OUTCOME (THI) AT FINAL VISIT
<i>45</i> .	TABLE S33: PER PROTOCOL 2 (N = 155) PRIMARY OUTCOME (THI) AT FINAL VISIT
45. 46.	TABLE S33: PER PROTOCOL 2 (N = 155) PRIMARY OUTCOME (THI) AT FINAL VISIT

Country	Clinical Site	Principal Investigator
Belgium	Katholieke Universiteit Leuven, Leuven	Asst. Prof. Dr. Rilana Cima Prof. Dr. Johan Vlaeyen
Germany	Tinnitus Center, Charité – Universitatsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin	Prof. Dr. Birgit Mazurek Dr. Benjamin Boecking
	University of Regensburg, Regensburg (RCT coordinator)	Prof. Dr. Berthold Langguth Prof. Dr. Martin Schecklmann Dr. Stefan Schoisswohl
Greece	Ethniko Kai Kapodistriako Panepistimo Athinon, Athens,	PD Dr. Dimitris Kikidis Assoc. Prof. Dr. Athanasios Bibas
Spain	Hospital Universitario Virgen de las Nieves, Granada Hospital Clinico Universitario San Cecilio, Granada	PD. Dr. Jose Antonio López- Escámez Dr. Juan Manuel Espinosa-Sanchez Dr. Patricia Perez Carpena

1. Table S1: Clinical Sites and Principal Investigators

2. Author Contributions

Author name	Contribution	Author name	Contribution
Stefan Schoisswohl, Ph.D.	Trial conceptualization and design; data acquisition; analysis; interpretation of the data; first draft	Marta Martinez- Martinez, M.D., Ph.D.	Data acquisition; revision
Laura Basso, Ph.D.	Analysis; interpretation of the data; first draft	Nicolas Muller-Locatelli, M.D.	Data acquisition; revision
Jorge Simoes, Ph.D.	Analysis; revision	Patrick Neff, Ph.D.	Trial conceptualization and design; revision
Milena Engelke, M.Sc.	Analysis; interpretation of the data, first draft	Uli Niemann, Dr. Ing.	Analysis; revision
Berthold Langguth, M.D.	Trial conceptualization and design; interpretation of the data; revision	Patricia Perez-Carpena, M.D., Ph.D.	Data acquisition; revision
Birgit Mazurek, M.D., Ph.D	Trial conceptualization and design; interpretation of the data; revision	Rüdiger Pryss, Ph.D.	Data acquisition; revision
Jose Antonio Lopez- Escamez, M.D., Ph.D.	Trial conceptualization and design; interpretation of the data; revision	Clara Puga, M.Sc.	Analysis; revision
Dimitrios Kikidis, M.D., Ph.D.	Trial conceptualization and design; interpretation of the data; revision	Paula Robles-Bolivar, M.Sc.	Data acquisition; revision
Rilana Cima, Ph.D.	Trial conceptualization and design; interpretation of the data; revision	Matthias Rose, Ph.D.	Data acquisition; revision
Alberto Bernal- Robledano, M.Sc.	Data acquisition; revision	Martin Schecklmann, Ph.D.	Trial conceptualization and design; data acquisition; interpretation of the data; revision
Benjamin Boecking, Ph.D., DClinPsy.	Trial conceptualization and design; data acquisition; interpretation of the data; revision	Tabea Schiele, M.Sc.	Data acquisition; revision
Jan Bulla, Ph.D.	Analysis; revision	Miro Schleicher, M.Sc.	Analysis; revision
Christopher R. Cederroth, Ph.D.	Interpretation of the data; revision	Johannes Schobel, Ph.D.	Data acquisition; revision
Sam Denys, Ph.D.	Data acquisition; revision	Myra Spiliopoulou, Dr. habil.	Analysis; revision
Alba Escalera-Balsera, M.Sc.	Data acquisition; revision	Sabine Stark, Dipl Psych.	Data acquisition; revision
Alvaro Gallego- Martinez, Ph.D.	Data acquisition; revision	Susanne Staudinger, M.A.	Trial conceptualization and design; data acquisition; revision
Silvano Gallus, Ph.D.	Interpretation of the data; revision	Alexandra Stege, Ph.D.	Data acquisition; revision
Leire Hidalgo-Lopez, M.D.	Data acquisition; revision	Beat Toedtli, Ph.D.	Analysis; revision
Carlotta M. Jarach, M.Sc.	Analysis; revision	Ilias Trochidis, M.Sc.	Interpretation of the data; revision

Hafez Kader, M.Sc.	Analysis; revision	Vishnu Unnikrishnan, M.Sc.	Analysis; revision
Michael Koller, Ph.D.	Trial conceptualization and design; revision	Evgenia Vassou, M.Sc.	Data acquisition; revision
Alessandra Lugo, Ph.D.	Interpretation of the data; revision; revision	Nicolan Verhaert, M.D, Ph.D.	Data acquisition; revision
Steven C. Marcrum, Ph.D.	Trial conceptualization and design; data acquisition; first draft	Carsten Vogel, M.Sc.	Data acquisition; revision
Nikos Markatos, B.Sc. (Honors)	Data acquisition; revision	Zoi Zachou, M.D.	Data acquisition; revision
Juan Martin-Lagos, M.D.	Data acquisition; revision	Winfried Schlee. Ph.D.	Trial conceptualization and design; analysis; interpretation of the data; first draft

Note. All authors fulfilled the necessary requirement for authorship and agreed to be fully accountable for all aspects of the present work. All authors read and approved the final manuscript.

Frequency (Hz)	Minimum threshold (dB HL)	Maximum threshold (db HL)
125	10	60
250	10	60
500	20	65
1000	25	70
2000	35	75
3000	40	80
4000	45	80
6000	45	80

3. Table S2: Criteria for HA indication

Note. Minimum and maximum threshold (dB HL) per frequency used for the definition of HA indication.

Name	Profession		
Cognitive Behavioral Therapy			
Boecking, B.	Psychologist, Psychotherapist		
Cima, R.	Psychologist, Psychotherapist		
Schecklmann, M.	Psychologist, Psychotherapist		
Hearing Aid			
Dettling-Papargyris, J.	Hearing aid acoustician		
Kikidis, D.	Audiologist		
Marcrum, S. C.	Audiologist		
Mazurek, B.	ENT-Physician		
Oppel, K.	Hearing aid acoustician		
Schiele, T.	Doctoral student		
Schlee, W.	Psychologist		
Structured Counseling			
Engelke, M.	Psychologist		
Schlee, W.	Psychologist		
Sound Therapy			
Neff, P.	Psychologist		
Schlee, W.	Psychologist		

4. Table S3: Responsible Persons for the Conception of Treatments

5. Table S4: Representativeness of Study Participants

Category	Example
Condition under investigation	Chronic tinnitus. The Tinnitus persisted for a minimum of 6 months.
Sex	No sex effect was found for the primary outcome (THI) when comparing single versus combination treatments for chronic tinnitus. 41.2 % of the participants were female, 58.8% were male.
Age	No age effect was found for the primary outcome (THI) when comparing single versus combination treatments for chronic tinnitus. The average age was 51.1 years. In a study by Probst et al. 2017, it was reported that the majority of patients visiting the specialized tinnitus clinic in Regensburg are in the age range of 45 - 55 years.
Race or ethnic group	Race or ethnicity was not assessed. No conclusions can be drawn about the influence of race or ethnicity.
Geography	The 5 centers were located in four European countries: Germany (2), Greece, Netherlands, Spain. Conclusions about countries with dissimilar health care systems are limited.
Severity	The average THI score at baseline was 48.0, which is considered moderate tinnitus distress. Participants with slight or no distress at screening (THI < 18), were excluded from the study.
Other considerations	In this trial, we compared single versus combination treatment of four clinical intervention types typically used for tinnitus treatment: cognitive behavioral therapy, hearing aids, sound therapy, and structured counseling for a duration of 12 weeks. The treatments were implemented in a typical way. Conclusions about treatments with different implementations are limited.
Overall representativeness of this trial	This trial showed that combining a treatment of weak clinical efficacy with a treatment of stronger clinical efficacy leads to an improvement of the overall clinical outcome.
	We recognize that the trial was limited to only four different clinical intervention types and their combinations. We do not know whether other treatment combinations, which are not part of the trial, would be superior to their respective singe treatments.
	We cannot conclude about combination treatments with three or more clinical interventions.
	All treatments were implemented in a typical way; however, it would be possible to implement them differently or apply the treatment for a shorter or longer time. We do not know whether other implementation would have the same results.

<i>6</i> .	Table S5:	Excluded	Patients	from	Study	Participation
				,		····· r ····

	Ν
Not meeting inclusion criteria	
Primary complaint tinnitus	2
Chronic tinnitus (≥ six months)	1
Age between 18 and 80 years	2
A score of \geq 18 in the Tinnitus Handicap Inventory (THI; Newman et al., 1996) – at least mild tinnitus distress	32
A score of > 22 in the Montreal Cognitive Assessment (MoCa; Nasreddine et al., 2005) – absence of mild cognitive impairment	14
Ability and willingness to use the UNITI mobile applications on smartphones	4
Openness to use a HA (if indication and allocation to HA group)	-
Ability to understand and consent to the research (hearing ability, intellectual capacity)	-
Ability to participate in all relevant visits (no plans for e.g., long-term holidays or pregnancy)	-
Existing drug therapies with psychoactive substances (e.g., antidepressants or anticonvulsants) must be stable for at least 30 days at the beginning of the therapeutic intervention. The drug therapy should remain constant during the course of the study. Necessary changes do not constitute an exclusion criterion per se, but need to be recorded.	-
Meeting exclusion criteria	
Objective tinnitus or heartbeat-synchronous tinnitus as primary complaint	7
Otosclerosis / acoustic neuroma or other relevant ear disorders with fluctuation hearing	10
Present acute infections (acute otitis media, otitis externa, acute sinusitis)	1
Meniere's disease or similar syndromes (but not vestibular migraine)	2
Serious internal, neurological or psychiatric conditions	4
Epilepsy or other disorders of the central nervous system (e.g., brain tumor or encephalitis)	1
Clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start	-
Severe hearing loss – inability to communicate properly in the course of the study	11
One deaf ear	4
Missing written informed consent	1
Start of any other tinnitus related treatments, especially hearing aids, structured counseling, sound therapy (with special devices; expecting long term effects) or cognitive behavioral therapy in the last 3 months before the start of the study	3
Other reasons	
Stratification group completed	107
Personal reasons/ declined to participate	6
Artificial eardrum	1
Total number of excluded patients	213

7. Table S6: Quantity and Reasons of Drop-outs before Treatment Start per Treatment Arm

Treatment arm	Ν	Reasons (N)
СВТ	9	No time (2); unable to travel to clinic (2); rejected CBT (2); no internet connection (1); started another treatment (1); interested in HA (1)
НА	1	Declined to participate (1)
SC	4	Rejected SC (1); interested in HA (1); declined to participate (1); app treatment not started (1)
ST	1	No capacity for daily app usage (1)
CBT + HA	5	Unable to travel to clinic (1); rejected HA and CBT (1); No capacity for CBT (1); suspected Morbus Meniere (1); lost (1)
CBT + SC	11	No time (4); lost (2); financial reasons (1); job reasons (1); chronic fatigue syndrome (1); rejected CBT (1); rejected CBT & app treatment not started (1)
CBT + ST	9	Rejected CBT + ST (3); no time (3); lost (1); personal reasons (1); job reasons (1)
HA + SC	1	Unexpected personal problems (1)
HA + ST	1	Rejected HA (1)
SC + ST	4	Interested in HA (1); no time (1); suspected acoustic neuroma (1); app treatment not started (1)
Total number of drop-outs before treatment start	46	

8. Table S7: Quantity and Reasons of Drop-outs during Treatment per Treatment Arm – before Interim Visit

Treatment arm	Ν	Reasons (N)
СВТ	4	Issues with daily app measures (1); no time (1); health worsening (1); personal reasons (1)
НА	1	Rejected HA (1)
SC	2	Not satisfied with treatment (1); lack of benefit & issues with daily app measures (1)
ST	3	Tinnitus worsening (1); tinnitus worsening & not satisfied with app treatment; no time due to illness (1)
CBT + HA	-	-
CBT + SC	6	Unsatisfied with CBT (1); health reasons (1); lost (1); no benefit of CBT (1); job reasons (1); rejected CBT (1)
CBT + ST	6	Tinnitus worsening (1); lost (1); no time (1); unable to travel to clinic (1); rejected CBT (1); treatment termination after first CBT session (1)
HA + SC	-	-
HS + ST	-	-
SC + ST	3	Tinnitus worsening (1); no reasons (1); lost (1)
Total number of drop-outs during treatment – before interim visit	25	

9. Table S8: Quantity and Reasons of Drop-outs during Treatment per Treatment Arm – after Interim Visit

Treatment arm	N	Reasons (N)
СВТ	4	No time (2); unable to travel to clinic (1); job reasons (1)
НА	3	Lost (2); started another HA treatment (1)
SC	5	Tinnitus worsening (1); lost (1); lack of benefit (1); health worsening/ reasons (1); did not want to continue (1)
ST	3	Not satisfied with treatment (2); lost (1)
CBT + HA	1	No time (1)
CBT + SC	2	No time (1); no longer attends CBT sessions (1)
CBT + ST	4	No benefit of CBT (2); tinnitus worsening (1); lost (1)
HA + SC	-	-
HA + ST	1	App treatment was never started (1)
SC + ST	3	App treatment was never started (1); lost (1); did not want to come to clinic due to COVID-19 pandemic (1)
Total number of drop-outs during treatment – after interim visit	26	

Treatment arm	N	Reasons (N)		
СВТ	5	No response (3); health reasons (1); no reasons (1)		
НА	5	Job reasons (2); no response (2); no reasons (1)		
SC	11	No response (6); not interested in follow-up (3); no reasons (1); health reasons (1)		
ST	2	No response (1); not available for follow-up (1)		
CBT + HA	1	No response (1)		
CBT + SC	3	No response (1); not interested in follow-up (1); terminated follow- up too late (1)		
CBT + ST	1	Deceased (1)		
HA + SC	1	No response (1)		
HA + ST	3	No response (3)		
SC + ST	4	No response (2); wanted to discontinue (1); not available for follow- up (1)		
Total number of patients lost to follow-up	36			

10. Table S9: Quantity and Reasons of Patients lost to Follow-up

11. Figure S1: Extended Patients Flowchart (Intention-to-treat and Per-protocol Sample)



Note. A total of 674 patient were screened of whom 461 (ITT sample) met the trial inclusion criteria and were randomly assigned to one of ten treatment arms comprised of a single treatment or a combination of two treatments using a set of four different therapy approaches - cognitive-behavioral therapy (CBT), hearing aids (HA), structured counseling (SC), and sound therapy (ST). 230 were assigned to single treatments and 231 were assigned to combination treatments. 231 subjects were excluded during the screening process. Available data for the primary outcome (incl. missing data) per study visit and treatment arm can be seen. The number of treatment non-adherence, protocol violations and allocation errors are equally shown per treatment arm. From the sample of 194 patients for the per-protocol analysis, nine had missings in covariates relevant for the analysis, resulting in a sample of 185 patients used for the per-protocol analysis.

Characteristics	CBT (N=56)	HA (N=59)	SC (N=56)	ST (N=59)	CBT + HA (N=17)	CBT + SC (N=51)	CBT + ST (N=54)	HA + SC (N=19)	HA + ST (N=27)	SC + ST (N=63)	Total (N=461)
Education — no. (%)											
Elementary or middle school	11 (21.2%)	18 (30.5%)	12 (21.8%)	12 (21.4%)	7 (43.8%)	20 (41.7%)	10 (20.0%)	4 (21.1%)	6 (22.2%)	17 (27.0%)	117 (26.3%)
High school	10 (19.2%)	10 (16.9%)	12 (21.8%)	16 (28.6%)	2 (12.5%)	7 (14.6%)	11 (22.0%)	6 (31.6%)	6 (22.2%)	13 (20.6%)	93 (20.9%)
University	31 (59.6%)	31 (52.5%)	31 (56.4%)	28 (50.0%)	7 (43.8%)	21 (43.8%)	29 (58.0%)	9 (47.4%)	15 (55.6%)	33 (52.4%)	235 (52.8%)
Tinnitus Presentation											
(ESIT-SQ B2) — no.											
(%)											
constant	48 (94.1%)	57 (96.6%)	49 (92.5%)	51 (94.4%)	13 (86.7%)	44 (93.6%)	45 (93.8%)	18 (100%)	26 (100%)	57 (90.5%)	408 (94.0%)
intermittent	3 (5.88%)	2 (3.39%)	4 (7.55%)	3 (5.56%)	2 (13.3%)	3 (6.38%)	3 (6.25%)	0 (0%)	0 (0%)	6 (9.52%)	26 (5.99%)
Tinnitus Loudness											
[dB] (Tinnitus											
Matching)	25.2 (21.6)	42.0 (21.1)	22.0 (22.0)	27 4 (22 1)	40 7 (10 0)	27.0 (10.1)	27 4 (10 6)	110 (07 ()	51 4 (10 0)	20.0 (21.0)	20.0 (21.7)
Mean (SD)	35.3 (21.6)	42.0 (21.1)	32.8 (23.0)	37.4 (23.1)	48.7 (18.6)	37.9 (19.1)	37.4 (18.6)	44.9 (27.6)	51.4 (19.9)	38.0 (21.8)	38.8 (21.7)
Median [Min, Max]	37.3 [1, 83]	46.0 [0, 82.5]	30.0 [2.5, 88]	35.0 [5, 90]	48.0 [20, 78]	40.5 [0, 75]	35.0 [5, 85]	41.3 [0, 100]	53.8 [10, 95]	35.0 [2.50, 92]	40.0 [0, 100]
Residual inhibition:											
Both ears — no. (%)											
none	17 (70.8%)	10 (41.7%)	11 (45.8%)	16 (50.0%)	3 (42.9%)	14 (56.0%)	17 (53.1%)	5 (50.0%)	8 (57.1%)	17 (48.6%)	118 (52.0%)
partially	5 (20.8%)	10 (41.7%)	8 (33.3%)	8 (25.0%)	2 (28.6%)	5 (20.0%)	7 (21.9%)	4 (40.0%)	5 (35.7%)	7 (20.0%)	61 (26.9%)
complete	2 (8.33%)	4 (16.7%)	5 (20.8%)	8 (25.0%)	2 (28.6%)	6 (24.0%)	8 (25.0%)	1 (10.0%)	1 (7.14%)	11 (31.4%)	48 (21.1%)
Residual inhibition:											
Left ear — no. (%)											
none	9 (50.0%)	10 (62.5%)	9 (56.3%)	10 (71.4%)	2 (66.7%)	7 (63.6%)	7 (70.0%)	3 (75.0%)	1 (16.7%)	4 (33.3%)	62 (56.4%)
partially	5 (27.8%)	2 (12.5%)	1 (6.25%)	2 (14.3%)	0 (0%)	2 (18.2%)	1 (10.0%)	1 (25.0%)	3 (50.0%)	6 (50.0%)	23 (20.9%)
complete	4 (22.2%)	4 (25.0%)	6 (37.5%)	2 (14.3%)	1 (33.3%)	2 (18.2%)	2 (20.0%)	0 (0%)	2 (33.3%)	2 (16.7%)	25 (22.7%)
Residual inhibition:											
Right ear — no. (%)											
none	9 (60.0%)	12 (63.2%)	11 (78.6%)	10 (90.9%)	5 (83.3%)	10 (66.7%)	6 (75.0%)	3 (60.0%)	3 (60.0%)	6 (54.5%)	75 (68.8%)
partially	2 (13.3%)	4 (21.1%)	1 (7.14%)	0 (0%)	0 (0%)	1 (6.67%)	1 (12.5%)	2 (40.0%)	0 (0%)	3 (27.3%)	14 (12.8%)
complete	4 (26.7%)	3 (15.8%)	2 (14.3%)	1 (9.09%)	1 (16.7%)	4 (26.7%)	1 (12.5%)	0 (0%)	2 (40.0%)	2 (18.2%)	20 (18.3%)
WHO-QoL 1 score: Physical health											
Mean (SD)	12.4 (1.73)	12.5 (1.78)	12.4 (1.84)	11.8 (2.10)	13.0 (1.62)	12.9 (2.04)	12.6 (1.57)	13.1 (1.26)	12.7 (2.11)	12.7 (1.96)	12.5 (1.87)
Median [Min, Max]	13.0 [7, 15]	13.0 [7, 15]	13.0 [7, 17]	11.5 [7, 16]	13.0 [10, 16]	13.0 [9, 17]	13.0 [10, 15]	13.0 [11, 15]	13.0 [10, 17]	13.0 [8, 17]	13.0 [7, 17]

12. Table S10: Demographic and clinical characteristics of the participants at baseline (stratified by treatment arm).

Characteristics	CBT (N=56)	HA (N=59)	SC (N=56)	ST (N=59)	CBT + HA (N=17)	CBT + SC (N=51)	CBT + ST (N=54)	HA + SC (N=19)	HA + ST (N=27)	SC + ST (N=63)	Total (N=461)
WHO-QoL 2 score:											
Psychological health											
Mean (SD)	13.3 (1.92)	13.6 (1.61)	13.5 (1.99)	13.2 (2.02)	13.9 (1.03)	14.1 (1.84)	13.7 (1.72)	14.2 (1.48)	13.3 (2.09)	13.5 (1.95)	13.6 (1.85)
Median [Min, Max]	13.0 [8, 17]	14.0 [9, 16]	14.0 [9, 18]	13.0 [6, 17]	14.0 [12, 16]	14.0 [10, 17]	14.0 [11, 17]	14.0 [11, 17]	13.0 [8, 17]	14.0 [9, 17]	14.0 [6, 18]
WHO-QoL 3 score:											
Social factors											
Mean (SD)	14.5 (3.27)	14.3 (3.15)	14.5 (3.03)	14.0 (3.11)	14.6 (2.83)	14.8 (3.01)	14.6 (3.15)	15.1 (2.78)	14.6 (3.14)	14.9 (2.96)	14.5 (3.06)
Median [Min, Max]	15.0 [8, 20]	15.0 [5, 20]	15.0 [8, 20]	15.0 [4, 20]	15.0 [9, 20]	15.0 [8, 20]	15.0 [9, 20]	15.5 [9, 20]	15.0 [8, 20]	16.0 [7, 20]	15.0 [4, 20]
WHO-QoL 4 score:											
Environment											
Mean (SD)	15.8 (2.09)	15.9 (2.15)	15.7 (2.59)	15.5 (2.35)	16.1 (1.82)	16.4 (1.93)	15.6 (1.92)	15.8 (1.77)	15.7 (2.38)	16.0 (2.30)	15.8 (2.18)
Median [Min, Max]	16.0 [11, 20]	16.0 [8, 20]	16.0 [9, 20]	15.5 [9, 20]	16.0 [13, 19]	16.0 [13, 20]	16.0 [12, 20]	15.5 [13, 19]	16.0 [11, 20]	16.0 [12, 20]	16.0 [8, 20]

Note. Tinnitus loudness level in dB was obtained by tinnitus matching, with higher values indicating greater perceived tinnitus loudness.

Residual inhibition is the brief tinnitus suppression following acoustic stimulation.

WHO-QoL scores range from 4 to 20, with higher scores indicating higher quality of life in the respective domain.

Treatment arm	Adverse event	Treatment arm	Adverse event
CBT	Reconstruction nasal septum	CBT + HA	Herpes zoster (thigh)
(n = 13)	Thoracic strain	(n = 5)	Skin Excision
	Additional burden due to husband's		Mental breakdown
	temporary absence		
	Cold		Invasion Russia
	Diverticulitis disease		Ear pain due to hearing aids
	Torn tendon on the foot	CBT + SC	Vaccine reaction (Moderna)
	Sickness of spouse	(n = 12)	Lithotripsy
	Toothache		Total endoprosthesis hip
	Cold (suspected Covid-19 positiv)		Leukoplakia vocal cord (surgery)
	Gastrointestinal infection	-	Chronic Fatigue Syndrom
	Worsening general health status	_	Vaccination reaction
	Death of close friend		Death of the cat, depressive
		-	symptoms of the significant other
	Worries about pet	-	Severe health problems of partner
HA	Mole removal	-	Angina
(n = 10)	Acute Urine Retention	-	Death of pet
	Tinnitus worsening		Heavy cold
	Retinal tear		Inheritance dispute with siblings
	Loss of mother in law	CBI + SI	Could 10 infection
	Loss of model-m-law	(n = 13)	A cute pain testis (left)
	Sleep problems		Covid-19 infection
	Covid-19 infection		Bereavement in the family
	Covid-19 infection	-	Cold
SC	Thyroid nodule (benign)		Mild temporary hearing loss
(n - 11)	Aggravation of tinnitus		Dizzvness
(n-11)	Diverticulitis	-	Worsening psychological health due
			to irritabile colon or depression
	Tooth extraction		Sleep rhythym disturbed
	Septoplasty		Invasion Russia
	Stye		Covid-19 infection
	Professional reorientation		Tinnitus worsening
	Parents-in-law's dementia	HA + SC	Broken foot
	exacerbation	(n = 3)	
	Bicyle accident		Ear infection due to hearing aid
	Additional task at work	TT (CT	Toothache
	Shoulder pain	HA + ST	Inflammation of the ear
ST	Surgery hand (plate removal)	(n = 5)	Frozen Shoulder
(n = 15)	Burglary Biavala aggident	-	Savera cold
	Influenze	-	Work strong
	Vaccine reaction (Covid 10)	SC ST	I ymph node removal (groin)
	Depression	5C + 5I	Forthcoming divorce
	Tooth infection and extraction	(n = 11)	A lot of stress at the beginning of the
	rooth infection and extraction		school vear
	Great workload and stress		Covid-19 infection
	Sprained foot	1	Migraine
	Disastrous vacation		Tinnitus worsening
	Cold		Tinnitus worsening
	Cold]	Accident
	Persistent tiredness]	Stress at work
	Gastrointestinal infection]	Bicycle accident
	Tinnitus unchanged but more present		Conflict with spouse
	and therefore more bothersome		

13. Table S11: Quantity and Type of Adverse Events per Treatment Arm





Note: Blue (0): Distribution of observed THI values (all visits). Red (1-50): Distribution of imputed THI values in all imputed data sets (all visits).



15. Figure S3: Audiogram in Patients With and Without Hearing Aid Indication for Single and Combined Treatment Groups

Note. Pooled audiogram for patients (A) with hearing aid indication and (B) without hearing aid indication separated for single and combined treatment groups measured by pure tone audiometry at baseline visit according to the guidelines of the British Society of Audiology. Error bars represent standard deviation.



16. Figure S4: Audiogram for Patients in all Treatment Groups

Note. Pooled audiograms of patients in all treatment groups measured by pure tone audiometry at baseline visit according to the guidelines of the British Society of Audiology. Error bars represent standard deviation.

Characteristic	Beta	95% CI ¹	p-value
visit_type			
baseline		_	
interim_visit	-10.497	-12.622, -8.373	<0.001
final_visit	-14.864	-16.998, -12.730	<0.001
followup_1	-13.306	-15.522, -11.090	<0.001
objective_1			
Combination	_	_	
Single	-0.178	-3.293, 2.938	0.911
sex			
female		_	
male	-0.891	-3.690, 1.908	0.532
age_baseline	-0.034	-0.154, 0.086	0.575
ha_indication			
ha		_	
no_ha	-3.509	-6.367, -0.650	0.016
phq9_score_baseline	2.132	1.852, 2.411	<0.001
esitsq_a5_education_baseline			
elementary_middle		_	
high_school	1.949	-2.182, 6.079	0.355
university	-3.428	-6.921, 0.065	0.054
visit_type * objective_1			
interim_visit * Single	2.647	-0.376, 5.669	0.086
final_visit * Single	3.159	0.235, 6.083	0.034
followup_1 * Single	1.382	-1.632, 4.396	0.368
¹ CI = Confidence Interval			

17. Table S12: Primary Outcome (THI) Objective 1: Model parameters

Contrast	Change from baseline (Hearing aid indication: yes)	Change from baseline (Hearing aid indication: no)
CBT	-10.4 [-20.9, 0]	-20.2 [-27.1, -13.2]
CBT + HA	-15.2 [-26, -4.5]	NA
CBT + SC	-18.6 [-28.3, -8.9]	-16.7 [-25.1, -8.4]
CBT + ST	-11.4 [-21.3, -1.6]	-15.3 [-22.4, -8.2]
HA	-14.4 [-19.6, -9.2]	NA
HA + SC	-20 [-29.2, -10.9]	NA
HA + ST	-12.9 [-20.5, -5.4]	NA
SC	-12.8 [-22.5, -3.1]	-11.6 [-18.3, -4.8]
SC + ST	-13.1 [-22.4, -3.9]	-12.5 [-18.7, -6.3]
ST	-3 [-12, 6.1]	-4.3 [-10.9, 2.4]

18. Table S13: THI change from baseline to final visit for hearing aid indication (yes/no)

Note. 95% CI in square brackets.

Contrast	Change from baseline (High tinnitus distress severity)	Change from baseline (Low tinnitus distress severity)		
CBT	-25 [-34.2, -15.8]	-9.3 [-16, -2.5]		
CBT + HA	-18.7 [-36.6, -0.8]	-12.2 [-24, -0.3]		
CBT + SC	-24.4 [-33.7, -15.1]	-10.6 [-18.6, -2.6]		
CBT + ST	-23.2 [-32.2, -14.3]	-6.2 [-13.1, 0.7]		
НА	-18.1 [-26.1, -10.1]	-10.6 [-17.2, -4.1]		
HA + SC	-26.9 [-41.6, -12.2]	-13.8 [-24.5, -3.2]		
HA + ST	ST -12.8 [-24.4, -1.2] -13.1 [-22.4, -3.8]			
SC	-15.6 [-24.6, -6.7]	-8.8 [-15.2, -2.5]		
SC + ST	-19.1 [-27.8, -10.5]	-7.8 [-13.5, -2.1]		
ST	-6.3 [-14.6, 2.1]	-1.5 [-7.8, 4.8]		

19. Table S14: THI change from baseline to final visit for high and low tinnitus distress severity

Note. 95% CI in square brackets. High tinnitus distress severity: THI \ge 48 at Screening. Low tinnitus distress severity: THI < 48 at Screening.



20. Figure S5: Primary Outcome (THI) Objective 1: Model Assumptions

Note. Model assumptions are plotted for the first of the 50 imputed datasets.





Note. Total THI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus. Error bars represent 95% confidence intervals. Sample sizes: CBT: N = 56, HA: N = 59, SC: N = 56, ST: N = 59, CBT + HA: N = 17, CBT + SC: N = 51, CBT + ST: N = 54, HA + SC: N = 19, HA + ST: N = 27, SC + ST: N = 63.

Contrast (baseline – final visit)	Estimate	95% CI	р	p-adjusted
CBT - (CBT + HA)	1.62	[-7.47, 10.71]	.727	1.00
CBT - (CBT + SC)	-0.53	[-7.01, 5.96]	.874	1.00
CBT - (CBT + ST)	2.77	[-3.56, 9.11]	.391	1.00
CBT - HA	2.46	[-3.50, 8.42]	.419	1.00
CBT - (HA + SC)	-3.18	[-11.50, 5.15]	.454	1.00
CBT - (HA + ST)	3.93	[-3.43, 11.29]	.295	1.00
CBT - SC	4.86	[-1.26, 10.98]	.119	1.00
CBT - (SC + ST)	4.21	[-1.70, 10.11]	.162	1.00
CBT - ST	13.03	[6.85, 19.21]	< .001***	< .001***
(CBT + HA) - (CBT + SC)	-2.14	[-11.60, 7.31]	.656	1.00
(CBT + HA) - (CBT + ST)	1.16	[-8.30, 10.61]	.811	1.00
(CBT + HA) - HA	0.84	[-8.24, 9.92]	.856	1.00
(CBT + HA) - (HA + SC)	-4.80	[-15.57, 5.98]	.383	1.00
(CBT + HA) - (HA + ST)	2.31	[-7.81, 12.43]	.654	1.00
(CBT + HA) - SC	3.24	[-5.97, 12.45]	.490	1.00
(CBT + HA) - (SC + ST)	2.59	[-6.56, 11.74]	.579	1.00
(CBT + HA) - ST	11.41	[2.21, 20.62]	.015*	.675
(CBT + SC) - (CBT + ST)	3.30	[-3.38, 9.98]	.333	1.00
(CBT + SC) - HA	2.98	[-3.30, 9.26]	.352	1.00
(CBT + SC) - (HA + SC)	-2.65	[-11.13, 5.83]	.540	1.00
(CBT + SC) - (HA + ST)	4.46	[-3.02, 11.93]	.242	1.00
(CBT + SC) - SC	5.39	[-1.05, 11.83]	.101	1.00
(CBT + SC) - (SC + ST)	4.73	[-1.43, 10.90]	.132	1.00
(CBT + SC) - ST	13.56	[7.21, 19.90]	< .001***	< .001***
(CBT + ST) - HA	-0.32	[-6.22, 5.59]	.916	1.00
(CBT + ST) - (HA + SC)	-5.95	[-14.30, 2.40]	.162	1.00
(CBT + ST) - (HA + ST)	1.16	[-6.07, 8.38]	.753	1.00
(CBT + ST) - SC	2.09	[-3.94, 8.11]	.497	1.00
(CBT + ST) - (SC + ST)	1.43	[-4.47, 7.34]	.634	1.00
(CBT + ST) - ST	10.26	[4.32, 16.19]	.001**	.045*
HA - (HA + SC)	-5.63	[-13.75, 2.48]	.173	1.00

22. Table S15: Primary Outcome (THI) Objective 2: Post-hoc Comparisons (Baseline to Final Visit)

Contrast (baseline – final visit)	Estimate	95% CI	р	p-adjusted
HA - (HA + ST)	1.48	[-5.56, 8.51]	.681	1.00
HA - SC	2.40	[-3.36, 8.17]	.413	1.00
HA - (SC + ST)	1.75	[-3.84, 7.34]	.539	1.00
HA - ST	10.57	[4.78, 16.37]	< .001***	< .001***
(HA + SC) - (HA + ST)	7.11	[-2.05, 16.27]	.128	1.00
(HA + SC) - SC	8.04	[-0.09, 16.16]	.053	1.00
(HA + SC) - (SC + ST)	7.38	[-0.65, 15.42]	.072	1.00
(HA + SC) - ST	16.21	[8.06, 24.36]	< .001***	< .001***
(HA + ST) - SC	0.93	[-6.23, 8.09]	.799	1.00
(HA + ST) - (SC + ST)	0.28	[-6.75, 7.30]	.939	1.00
(HA + ST) - ST	9.10	[2.03, 16.16]	.012*	.540
SC - (SC + ST)	-0.65	[-6.39, 5.08]	.823	1.00
SC - ST	8.17	[2.29, 14.05]	.006**	.270
(SC + ST) - ST	8.82	[3.20, 14.45]	.002**	.090

Note. Objective 2: Pairwise comparison of treatments for the THI difference from baseline to final visit (post-hoc tests). P-values were adjusted for multiple comparisons using the Bonferroni method. *p<0.05, **p<0.01, ***p<0.001.

Objective	Contrast	Change_from_baseline	95% CI
4_A	Doesnt_have_CBT	-11.57	[-14.01, -9.14]
4_A	Has_CBT	-16.02	[-19.33, -12.70]
4_B	Doesnt_have_HA	-11.42	[-15.47, -7.38]
4_B	Has_HA	-15.07	[-18.75, -11.39]
4_C	Doesnt_have_SC	-12.46	[-15.01, -9.91]
4_C	Has_SC	-14.48	[-17.62, -11.34]
4_D	Doesnt_have_ST	-15.48	[-18.23, -12.72]
4_D	Has_ST	-10.51	[-13.43, -7.58]
5	Brain	-15.36	[-18.82, -11.89]
5	Brain_and_Ear	-14.36	[-17.69, -11.04]
5	Ear	-9.83	[-13.20, -6.45]

23. Table S16: Primary Outcome (THI) Objective 4 & 5 at Final Visit

Note. Objective 4: Treatments with vs. treatments without; Objective 5: Ear mediated vs. brain mediated vs. ear and brain mediated treatments

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-10.50	[-13.28, -7.71]
1	Single	-7.85	[-10.66, -5.04]
2	СВТ	-10.13	[-15.87, -4.38]
2	CBT + HA	-11.24	[-21.70, -0.78]
2	CBT + SC	-10.84	[-17.15, -4.54]
2	CBT + ST	-10.22	[-15.90, -4.55]
2	НА	-11.45	[-16.63, -6.27]
2	HA + SC	-12.37	[-21.53, -3.21]
2	HA + ST	-7.95	[-15.61, -0.29]
2	SC	-9.05	[-14.60, -3.50]
2	SC + ST	-10.78	[-15.99, -5.57]
2	ST	-0.95	[-6.25, 4.35]
3_A	Combi_CBT	-10.62	[-14.57, -6.68]
3_A	Single_CBT	-10.13	[-15.92, -4.33]
3_B	Combi_HA	-10.17	[-15.05, -5.28]
3_B	Single_HA	-11.45	[-16.42, -6.48]
3_C	Combi_SC	-11.03	[-14.72, -7.34]
3_C	Single_SC	-9.05	[-14.60, -3.50]
3_D	Combi_ST	-10.04	[-13.57, -6.51]
3_D	Single_ST	-0.95	[-6.35, 4.46]
4_A	Doesnt_have_CBT	-8.36	[-10.83, -5.90]
4_A	Has_CBT	-10.47	[-13.70, -7.23]
4_B	Doesnt_have_HA	-7.77	[-11.79, -3.76]
4_B	Has_HA	-10.79	[-14.39, -7.19]
4_C	Doesnt_have_SC	-8.30	[-10.87, -5.72]
4_C	Has_SC	-10.44	[-13.54, -7.35]
4_D	Doesnt_have_ST	-10.58	[-13.23, -7.92]
4_D	Has_ST	-7.40	[-10.34, -4.45]
5	Brain	-9.98	[-13.33, -6.63]
5	Brain_and_Ear	-10.83	[-14.19, -7.47]
5	Ear	-6.53	[-9.91, -3.14]

24. Table S17: Primary Outcome (THI) at Interim Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-13.31	[-16.21, -10.40]
1	Single	-11.92	[-14.75, -9.09]
2	CBT	-17.32	[-23.06, -11.58]
2	CBT + HA	-11.94	[-22.40, -1.48]
2	CBT + SC	-16.32	[-22.60, -10.04]
2	CBT + ST	-13.91	[-19.62, -8.20]
2	НА	-13.27	[-18.70, -7.83]
2	HA + SC	-15.17	[-24.62, -5.71]
2	HA + ST	-10.53	[-18.65, -2.41]
2	SC	-11.50	[-17.55, -5.44]
2	SC + ST	-11.35	[-16.77, -5.92]
2	ST	-5.87	[-11.18, -0.55]
3_A	Combi_CBT	-14.64	[-18.56, -10.72]
3_A	Single_CBT	-17.32	[-23.11, -11.53]
3_B	Combi_HA	-12.31	[-17.40, -7.21]
3_B	Single_HA	-13.27	[-18.51, -8.03]
3_C	Combi_SC	-13.80	[-17.67, -9.93]
3_C	Single_SC	-11.50	[-17.55, -5.44]
3_D	Combi_ST	-12.15	[-15.79, -8.52]
3_D	Single_ST	-5.87	[-11.28, -0.45]
4_A	Doesnt_have_CBT	-10.81	[-13.39, -8.23]
4_A	Has_CBT	-15.49	[-18.75, -12.22]
4_B	Doesnt_have_HA	-11.46	[-15.62, -7.29]
4_B	Has_HA	-12.77	[-16.59, -8.95]
4_C	Doesnt_have_SC	-12.27	[-14.90, -9.64]
4_C	Has_SC	-13.12	[-16.48, -9.75]
4_D	Doesnt_have_ST	-14.42	[-17.15, -11.69]
4_D	Has_ST	-10.33	[-13.30, -7.36]
5	Brain	-15.01	[-18.56, -11.45]
5	Brain_and_Ear	-12.79	[-16.23, -9.35]
5	Ear	-9.75	[-13.22, -6.28]

25. Table S18: Primary Outcome (THI) at Follow-up

Objective	Contrast	Change_from_baseline	95% CI
4_A	Doesnt_have_CBT	-10.01	[-12.66, -7.36]
4_A	Has_CBT	-13.33	[-16.89, -9.78]
4_B	Doesnt_have_HA	-9.25	[-13.64, -4.86]
4_B	Has_HA	-14.19	[-18.09, -10.29]
4_C	Doesnt_have_SC	-12.21	[-14.96, -9.46]
4_C	Has_SC	-9.97	[-13.33, -6.61]
4_D	Doesnt_have_ST	-12.80	[-15.62, -9.99]
4_D	Has_ST	-9.37	[-12.56, -6.18]
5	Brain	-12.26	[-15.89, -8.64]
5	Brain_and_Ear	-11.13	[-14.86, -7.40]
5	Ear	-10.37	[-14.00, -6.73]

26. Table S19: Secondary Outcome (TFI) Objective 4 & 5 at Final Visit

Note. Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. ear- and brain-mediated treatments.

Objective	Contrast	Change_from_baseline	95% CI
4_A	Doesnt_have_CBT	-2.63	[-3.25, -2.02]
4_A	Has_CBT	-3.91	[-4.71, -3.10]
4_B	Doesnt_have_HA	-2.51	[-3.49, -1.53]
4_B	Has_HA	-3.28	[-4.16, -2.41]
4_C	Doesnt_have_SC	-3.05	[-3.69, -2.41]
4_C	Has_SC	-3.23	[-3.99, -2.48]
4_D	Doesnt_have_ST	-3.61	[-4.27, -2.95]
4_D	Has_ST	-2.50	[-3.24, -1.77]
5	Brain	-3.65	[-4.50, -2.80]
5	Brain_and_Ear	-3.30	[-4.15, -2.44]
5	Ear	-2.35	[-3.21, -1.50]

27. Table S20: Secondary Outcome (Mini-TQ) Objective 4 & 5 at Final Visit

Note. Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. earand brain-mediated treatments.

Objective	Contrast	Change_from_baseline	95% CI
4_A	Doesnt_have_CBT	-0.80	[-1.15, -0.45]
4_A	Has_CBT	-0.73	[-1.21, -0.25]
4_B	Doesnt_have_HA	-0.44	[-1.03, 0.15]
4_B	Has_HA	-1.10	[-1.63, -0.57]
4_C	Doesnt_have_SC	-0.79	[-1.15, -0.42]
4_C	Has_SC	-0.76	[-1.20, -0.31]
4_D	Doesnt_have_ST	-0.87	[-1.27, -0.48]
4_D	Has_ST	-0.64	[-1.05, -0.24]
5	Brain	-0.75	[-1.26, -0.24]
5	Brain_and_Ear	-0.68	[-1.17, -0.19]
5	Ear	-0.90	[-1.38, -0.42]

28. Table S21: Secondary Outcome (NRS-2: "How strong or loud is your tinnitus at present?") Objective 4 & 5 at Final Visit

Note. Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. earand brain-mediated treatments.

Objective	Contrast	Change_from_baseline	95% CI
4_A	Doesnt_have_CBT	-1.46	[-2.04, -0.88]
4_A	Has_CBT	-1.70	[-2.45, -0.95]
4_B	Doesnt_have_HA	-1.28	[-2.25, -0.32]
4_B	Has_HA	-1.90	[-2.76, -1.05]
4_C	Doesnt_have_SC	-1.62	[-2.22, -1.02]
4_C	Has_SC	-1.46	[-2.20, -0.73]
4_D	Doesnt_have_ST	-1.85	[-2.48, -1.23]
4_D	Has_ST	-1.17	[-1.87, -0.48]
5	Brain	-1.72	[-2.52, -0.93]
5	Brain_and_Ear	-1.36	[-2.17, -0.55]
5	Ear	-1.57	[-2.37, -0.77]

29. Table S22: Secondary Outcome (PHQ-9) Objective 4 & 5 at Final Visit

Note. Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. earand brain-mediated treatments



30. Figure S7: Secondary Outcome (CGI-I) at Final Visit – Single vs. Combination (Objective 1)

Note. Distribution (in percentage) of CGI-I (Clinical Global Impression Scale) at final visit for Objective 1.



31. Figure S8: Secondary Outcome (CGI-I) at Final Visit – all Treatment Arms (Objective 2)

Note. Distribution (in percentage) of CGI-I (Clinical Global Impression Scale) at final visit for Objective 2.



32. Figure S9: Secondary Outcome (CGI-I) at Final Visit – all Treatment Arms (Objective 2) in Patients With and Without Hearing Aid Indication

Note. Distribution (in percentage) of CGI-I (Clinical Global Impression Scale) at final visit for Objective 2 in patients (A) with hearing aid indication and (B) without hearing aid indication.



33. Figure S10: Secondary Outcome (CGI-I) at Final Visit – all Treatment Arms (Objective 2) in Patients with High and Low Tinnitus Distress Severity

Note. Distribution (in percentage) of CGI-I (Clinical Global Impression Scale) at final visit for Objective 2 in patients (A) with High and (B) Low tinnitus distress severity. High tinnitus distress severity: THI \geq 48 at Screening. Low tinnitus distress severity: THI < 48 at Screening.

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	0.29	[0.01, 0.58]
1	Single	0.42	[0.13, 0.71]
2	CBT	0.43	[-0.18, 1.04]
2	CBT + HA	0.49	[-0.64, 1.62]
2	CBT + SC	0.24	[-0.39, 0.88]
2	CBT + ST	0.36	[-0.23, 0.95]
2	НА	0.52	[-0.01, 1.06]
2	HA + SC	0.64	[-0.32, 1.60]
2	HA + ST	0.36	[-0.43, 1.15]
2	SC	0.20	[-0.39, 0.79]
2	SC + ST	0.10	[-0.44, 0.63]
2	ST	0.51	[-0.04, 1.07]
3_A	Combi_CBT	0.33	[-0.07, 0.73]
3_A	Single_CBT	0.43	[-0.17, 1.03]
3_B	Combi_HA	0.48	[-0.06, 1.01]
3_B	Single_HA	0.52	[-0.01, 1.06]
3_C	Combi_SC	0.23	[-0.15, 0.60]
3_C	Single_SC	0.20	[-0.38, 0.79]
3_D	Combi_ST	0.24	[-0.12, 0.61]
3_D	Single_ST	0.51	[-0.05, 1.07]
4_A	Doesnt_have_CBT	0.35	[0.10, 0.61]
4_A	Has_CBT	0.36	[0.02, 0.70]
4_B	Doesnt_have_HA	0.34	[-0.08, 0.75]
4_B	Has_HA	0.50	[0.13, 0.87]
4_C	Doesnt_have_SC	0.45	[0.18, 0.72]
4_C	Has_SC	0.22	[-0.10, 0.54]
4_D	Doesnt_have_ST	0.38	[0.11, 0.66]
4_D	Has_ST	0.32	[0.02, 0.62]
5	Brain	0.29	[-0.06, 0.64]
5	Brain_and_Ear	0.30	[-0.05, 0.65]
5	Ear	0.49	[0.14, 0.84]

34. Table S23: Secondary Outcome (WHO-QoL-Bref 1: Physical Health) at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	0.36	[0.07, 0.65]
1	Single	0.36	[0.08, 0.65]
2	CBT	0.33	[-0.25, 0.92]
2	CBT + HA	0.75	[-0.35, 1.86]
2	CBT + SC	0.28	[-0.35, 0.91]
2	CBT + ST	0.35	[-0.27, 0.97]
2	НА	0.35	[-0.18, 0.89]
2	HA + SC	0.15	[-0.81, 1.10]
2	HA + ST	0.41	[-0.37, 1.20]
2	SC	0.30	[-0.28, 0.88]
2	SC + ST	0.35	[-0.19, 0.89]
2	ST	0.47	[-0.09, 1.02]
3_A	Combi_CBT	0.38	[-0.05, 0.81]
3_A	Single_CBT	0.33	[-0.26, 0.93]
3_B	Combi_HA	0.43	[-0.08, 0.94]
3_B	Single_HA	0.35	[-0.16, 0.87]
3_C	Combi_SC	0.30	[-0.08, 0.68]
3_C	Single_SC	0.30	[-0.29, 0.89]
3_D	Combi_ST	0.36	[-0.01, 0.73]
3_D	Single_ST	0.47	[-0.10, 1.04]
4_A	Doesnt_have_CBT	0.36	[0.11, 0.61]
4_A	Has_CBT	0.36	[0.02, 0.70]
4_B	Doesnt_have_HA	0.34	[-0.09, 0.76]
4_B	Has_HA	0.39	[0.03, 0.75]
4_C	Doesnt_have_SC	0.40	[0.14, 0.66]
4_C	Has_SC	0.30	[-0.02, 0.61]
4_D	Doesnt_have_ST	0.34	[0.06, 0.61]
4_D	Has_ST	0.39	[0.09, 0.70]
5	Brain	0.31	[-0.05, 0.66]
5	Brain_and_Ear	0.37	[0.01, 0.73]
5	Ear	0.41	[0.06, 0.75]

35. Table S24: Secondary Outcome (WHO-QoL-Bref 2: Psychological Health) at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	0.17	[-0.26, 0.60]
1	Single	0.20	[-0.22, 0.63]
2	CBT	0.26	[-0.62, 1.14]
2	CBT + HA	0.49	[-1.14, 2.12]
2	CBT + SC	0.62	[-0.35, 1.59]
2	CBT + ST	0.14	[-0.76, 1.04]
2	НА	0.63	[-0.18, 1.43]
2	HA + SC	0.93	[-0.48, 2.34]
2	HA + ST	-0.09	[-1.27, 1.10]
2	SC	0.01	[-0.86, 0.88]
2	SC + ST	-0.38	[-1.19, 0.42]
2	ST	-0.09	[-0.93, 0.75]
3_A	Combi_CBT	0.39	[-0.23, 1.01]
3_A	Single_CBT	0.26	[-0.62, 1.14]
3_B	Combi_HA	0.38	[-0.40, 1.15]
3_B	Single_HA	0.63	[-0.16, 1.41]
3_C	Combi_SC	0.19	[-0.35, 0.73]
3_C	Single_SC	0.01	[-0.82, 0.84]
3_D	Combi_ST	-0.13	[-0.69, 0.43]
3_D	Single_ST	-0.09	[-0.97, 0.79]
4_A	Doesnt_have_CBT	0.08	[-0.31, 0.47]
4_A	Has_CBT	0.35	[-0.16, 0.86]
4_B	Doesnt_have_HA	0.30	[-0.34, 0.94]
4_B	Has_HA	0.50	[-0.07, 1.06]
4_C	Doesnt_have_SC	0.22	[-0.18, 0.62]
4_C	Has_SC	0.14	[-0.35, 0.62]
4_D	Doesnt_have_ST	0.43	[0.01, 0.84]
4_D	Has_ST	-0.12	[-0.58, 0.34]
5	Brain	0.29	[-0.24, 0.81]
5	Brain_and_Ear	0.06	[-0.47, 0.59]
5	Ear	0.20	[-0.32, 0.73]

36. Table S25: Secondary Outcome (WHO-QoL-Bref 3: Social Factors) at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	0.28	[-0.04, 0.61]
1	Single	0.35	[0.02, 0.67]
2	CBT	0.36	[-0.31, 1.02]
2	CBT + HA	0.57	[-0.72, 1.85]
2	CBT + SC	0.06	[-0.64, 0.75]
2	CBT + ST	0.46	[-0.21, 1.13]
2	НА	0.74	[0.14, 1.34]
2	HA + SC	0.66	[-0.44, 1.75]
2	HA + ST	0.35	[-0.53, 1.23]
2	SC	0.11	[-0.54, 0.76]
2	SC + ST	0.09	[-0.52, 0.71]
2	ST	0.17	[-0.47, 0.80]
3_A	Combi_CBT	0.31	[-0.13, 0.74]
3_A	Single_CBT	0.36	[-0.28, 0.99]
3_B	Combi_HA	0.50	[-0.11, 1.11]
3_B	Single_HA	0.74	[0.15, 1.33]
3_C	Combi_SC	0.16	[-0.27, 0.59]
3_C	Single_SC	0.11	[-0.56, 0.78]
3_D	Combi_ST	0.28	[-0.13, 0.69]
3_D	Single_ST	0.17	[-0.47, 0.81]
4_A	Doesnt_have_CBT	0.31	[0.02, 0.60]
4_A	Has_CBT	0.32	[-0.06, 0.71]
4_B	Doesnt_have_HA	0.29	[-0.20, 0.77]
4_B	Has_HA	0.62	[0.21, 1.02]
4_C	Doesnt_have_SC	0.43	[0.13, 0.73]
4_C	Has_SC	0.14	[-0.21, 0.50]
4_D	Doesnt_have_ST	0.37	[0.06, 0.67]
4_D	Has_ST	0.25	[-0.10, 0.59]
5	Brain	0.18	[-0.21, 0.57]
5	Brain_and_Ear	0.35	[-0.06, 0.75]
5	Ear	0.44	[0.04, 0.83]

37. Table S26: Secondary Outcome (WHO-QoL-Bref 4: Environment) at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-0.53	[-0.71, -0.35]
1	Single	-0.49	[-0.67, -0.31]
2	CBT	-0.53	[-0.94, -0.11]
2	CBT + HA	-0.87	[-1.55, -0.20]
2	CBT + SC	-0.54	[-0.93, -0.14]
2	CBT + ST	-0.57	[-0.95, -0.19]
2	НА	-0.60	[-0.94, -0.27]
2	HA + SC	-0.49	[-1.09, 0.11]
2	HA + ST	-0.58	[-1.07, -0.08]
2	SC	-0.61	[-0.98, -0.25]
2	SC + ST	-0.39	[-0.72, -0.05]
2	ST	-0.24	[-0.60, 0.12]
3_A	Combi_CBT	-0.60	[-0.86, -0.33]
3_A	Single_CBT	-0.53	[-0.96, -0.09]
3_B	Combi_HA	-0.63	[-0.95, -0.31]
3_B	Single_HA	-0.60	[-0.91, -0.29]
3_C	Combi_SC	-0.46	[-0.69, -0.23]
3_C	Single_SC	-0.61	[-0.96, -0.27]
3_D	Combi_ST	-0.49	[-0.72, -0.26]
3_D	Single_ST	-0.24	[-0.61, 0.13]
4_A	Doesnt_have_CBT	-0.47	[-0.63, -0.31]
4_A	Has_CBT	-0.58	[-0.79, -0.36]
4_B	Doesnt_have_HA	-0.38	[-0.65, -0.12]
4_B	Has_HA	-0.62	[-0.85, -0.39]
4_C	Doesnt_have_SC	-0.52	[-0.69, -0.35]
4_C	Has_SC	-0.50	[-0.71, -0.30]
4_D	Doesnt_have_ST	-0.58	[-0.75, -0.41]
4_D	Has_ST	-0.42	[-0.61, -0.23]
5	Brain	-0.56	[-0.78, -0.34]
5	Brain_and_Ear	-0.52	[-0.74, -0.30]
5	Ear	-0.45	[-0.67, -0.23]

38. Table S27: Secondary Outcome (NRS 1: "How much of a problem is your tinnitus at present?") at Final Visit

Note. Since the outcome is ordinally scaled, it was fitted as a sensitivity analysis with clmm of the ordinal package, as no differences were found to the mixed effect model, the results of the mixed effect model are reported here. Objective 1: Single vs. Combination (all treatments); Objective 2: All treatments against each other; Objective 3: Single vs. Combination (separately); Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. ear-and brain-mediated treatments.

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-1.68	[-2.13, -1.23]
1	Single	-1.25	[-1.70, -0.80]
2	CBT	-1.76	[-2.72, -0.80]
2	CBT + HA	-1.94	[-3.71, -0.17]
2	CBT + SC	-1.94	[-2.94, -0.93]
2	CBT + ST	-1.68	[-2.65, -0.72]
2	HA	-1.63	[-2.50, -0.77]
2	HA + SC	-1.22	[-2.76, 0.32]
2	HA + ST	-1.65	[-2.92, -0.38]
2	SC	-1.08	[-2.00, -0.16]
2	SC + ST	-1.55	[-2.42, -0.68]
2	ST	-0.55	[-1.44, 0.33]
3_A	Combi_CBT	-1.83	[-2.47, -1.18]
3_A	Single_CBT	-1.76	[-2.72, -0.80]
3_B	Combi_HA	-1.60	[-2.49, -0.71]
3_B	Single_HA	-1.63	[-2.52, -0.75]
3_C	Combi_SC	-1.65	[-2.25, -1.05]
3_C	Single_SC	-1.08	[-2.01, -0.15]
3_D	Combi_ST	-1.62	[-2.20, -1.03]
3_D	Single_ST	-0.55	[-1.45, 0.34]
4_A	Doesnt_have_CBT	-1.25	[-1.66, -0.85]
4_A	Has_CBT	-1.80	[-2.34, -1.27]
4_B	Doesnt_have_HA	-1.14	[-1.80, -0.47]
4_B	Has_HA	-1.62	[-2.22, -1.01]
4_C	Doesnt_have_SC	-1.46	[-1.87, -1.04]
4_C	Has_SC	-1.48	[-1.98, -0.98]
4_D	Doesnt_have_ST	-1.59	[-2.02, -1.16]
4_D	Has_ST	-1.31	[-1.80, -0.82]
5	Brain	-1.58	[-2.14, -1.02]
5	Brain_and_Ear	-1.60	[-2.16, -1.04]
5	Ear	-1.20	[-1.75, -0.64]

39. Table S28: Secondary Outcome (NRS 3: "How uncomfortable is your tinnitus at present?") at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-1.53	[-1.99, -1.08]
1	Single	-1.18	[-1.62, -0.73]
2	CBT	-1.58	[-2.55, -0.62]
2	CBT + HA	-2.00	[-3.73, -0.27]
2	CBT + SC	-1.83	[-2.84, -0.81]
2	CBT + ST	-1.29	[-2.23, -0.36]
2	НА	-1.63	[-2.49, -0.78]
2	HA + SC	-1.68	[-3.21, -0.16]
2	HA + ST	-1.16	[-2.42, 0.09]
2	SC	-1.03	[-1.97, -0.10]
2	SC + ST	-1.48	[-2.34, -0.63]
2	ST	-0.47	[-1.35, 0.42]
3_A	Combi_CBT	-1.61	[-2.26, -0.97]
3_A	Single_CBT	-1.58	[-2.55, -0.62]
3_B	Combi_HA	-1.55	[-2.43, -0.66]
3_B	Single_HA	-1.63	[-2.53, -0.73]
3_C	Combi_SC	-1.64	[-2.24, -1.04]
3_C	Single_SC	-1.03	[-1.96, -0.10]
3_D	Combi_ST	-1.35	[-1.93, -0.78]
3_D	Single_ST	-0.47	[-1.36, 0.43]
4_A	Doesnt_have_CBT	-1.20	[-1.61, -0.78]
4_A	Has_CBT	-1.60	[-2.13, -1.08]
4_B	Doesnt_have_HA	-1.14	[-1.81, -0.46]
4_B	Has_HA	-1.59	[-2.19, -0.98]
4_C	Doesnt_have_SC	-1.28	[-1.69, -0.87]
4_C	Has_SC	-1.46	[-1.98, -0.94]
4_D	Doesnt_have_ST	-1.56	[-1.99, -1.13]
4_D	Has_ST	-1.09	[-1.58, -0.61]
5	Brain	-1.47	[-2.02, -0.92]
5	Brain_and_Ear	-1.50	[-2.05, -0.94]
5	Ear	-1.07	[-1.62, -0.52]

40. Table S29: Secondary outcome (NRS 4: "How annoying is your tinnitus at present?") at final visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-1.71	[-2.26, -1.16]
1	Single	-1.20	[-1.74, -0.66]
2	CBT	-1.67	[-2.82, -0.52]
2	CBT + HA	-2.41	[-4.51, -0.30]
2	CBT + SC	-1.92	[-3.12, -0.73]
2	CBT + ST	-1.75	[-2.88, -0.63]
2	НА	-1.29	[-2.33, -0.25]
2	HA + SC	-0.87	[-2.73, 0.98]
2	HA + ST	-2.18	[-3.69, -0.66]
2	SC	-1.18	[-2.27, -0.10]
2	SC + ST	-1.36	[-2.39, -0.32]
2	ST	-0.68	[-1.72, 0.36]
3_A	Combi_CBT	-1.92	[-2.71, -1.12]
3_A	Single_CBT	-1.67	[-2.84, -0.50]
3_B	Combi_HA	-1.85	[-2.88, -0.81]
3_B	Single_HA	-1.29	[-2.33, -0.25]
3_C	Combi_SC	-1.50	[-2.22, -0.79]
3_C	Single_SC	-1.18	[-2.26, -0.11]
3_D	Combi_ST	-1.66	[-2.35, -0.97]
3_D	Single_ST	-0.68	[-1.75, 0.39]
4_A	Doesnt_have_CBT	-1.21	[-1.69, -0.74]
4_A	Has_CBT	-1.84	[-2.49, -1.19]
4_B	Doesnt_have_HA	-0.95	[-1.73, -0.16]
4_B	Has_HA	-1.58	[-2.29, -0.87]
4_C	Doesnt_have_SC	-1.49	[-1.99, -0.99]
4_C	Has_SC	-1.41	[-2.01, -0.80]
4_D	Doesnt_have_ST	-1.52	[-2.05, -0.99]
4_D	Has_ST	-1.37	[-1.94, -0.81]
5	Brain	-1.58	[-2.26, -0.90]
5	Brain_and_Ear	-1.55	[-2.22, -0.88]
5	Ear	-1.21	[-1.87, -0.55]

41. Table S30: Secondary outcome (NRS 5: "How easy is it for you to ignore your tinnitus at present?") at final visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-1.37	[-1.83, -0.91]
1	Single	-1.16	[-1.61, -0.71]
2	СВТ	-1.31	[-2.31, -0.31]
2	CBT + HA	-1.93	[-3.64, -0.23]
2	CBT + SC	-1.93	[-2.90, -0.97]
2	CBT + ST	-1.11	[-2.06, -0.16]
2	НА	-1.40	[-2.24, -0.55]
2	HA + SC	-1.32	[-2.81, 0.16]
2	HA + ST	-1.38	[-2.61, -0.15]
2	SC	-1.14	[-2.05, -0.24]
2	SC + ST	-1.00	[-1.83, -0.16]
2	ST	-0.80	[-1.65, 0.05]
3_A	Combi_CBT	-1.57	[-2.22, -0.92]
3_A	Single_CBT	-1.31	[-2.31, -0.31]
3_B	Combi_HA	-1.51	[-2.39, -0.64]
3_B	Single_HA	-1.40	[-2.29, -0.50]
3_C	Combi_SC	-1.40	[-1.98, -0.82]
3_C	Single_SC	-1.14	[-2.04, -0.25]
3_D	Combi_ST	-1.11	[-1.70, -0.52]
3_D	Single_ST	-0.80	[-1.67, 0.07]
4_A	Doesnt_have_CBT	-1.13	[-1.52, -0.73]
4_A	Has_CBT	-1.49	[-2.03, -0.95]
4_B	Doesnt_have_HA	-1.01	[-1.67, -0.36]
4_B	Has_HA	-1.46	[-2.05, -0.86]
4_C	Doesnt_have_SC	-1.22	[-1.64, -0.81]
4_C	Has_SC	-1.33	[-1.82, -0.83]
4_D	Doesnt_have_ST	-1.46	[-1.89, -1.03]
4_D	Has_ST	-1.02	[-1.49, -0.55]
5	Brain	-1.45	[-2.01, -0.89]
5	Brain_and_Ear	-1.18	[-1.74, -0.62]
5	Ear	-1.15	[-1.69, -0.61]

42. Table S31: Secondary outcome (NRS 6: "How unpleasant is your tinnitus at present?") at final visit



43. Figure S11: Per protocol (N = 185) Primary outcome (THI)

Note. Change from Baseline in THI total score to interim visit (6w), final visit (12w) and follow-up (36w) for A) single and combination treatments; B) all treatments; C) CBT + HA; D) CBT + SC; E) CBT + ST; F) HA + SC; G) HA + ST; and H) SC + ST. Total THI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus. Error bars represent 95% confidence intervals.

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-15.27	[-19.68, -10.86]
1	Single	-12.47	[-16.10, -8.84]
2	CBT	-18.53	[-25.35, -11.72]
2	CBT + HA	-10.00	[-31.55, 11.55]
2	CBT + SC	-22.00	[-34.44, -9.56]
2	CBT + ST	-17.29	[-26.35, -8.24]
2	НА	-16.33	[-23.15, -9.52]
2	HA + SC	-12.00	[-30.67, 6.67]
2	HA + ST	-10.46	[-20.82, -0.11]
2	SC	-11.11	[-19.91, -2.31]
2	SC + ST	-15.10	[-22.19, -8.01]
2	ST	-3.64	[-10.38, 3.10]
3_A	Combi_CBT	-18.00	[-25.29, -10.71]
3_A	Single_CBT	-18.53	[-25.70, -11.36]
3_B	Combi_HA	-10.70	[-18.27, -3.13]
3_B	Single_HA	-16.33	[-22.52, -10.15]
3_C	Combi_SC	-16.36	[-22.06, -10.66]
3_C	Single_SC	-11.11	[-19.68, -2.54]
3_D	Combi_ST	-14.70	[-19.71, -9.69]
3_D	Single_ST	-3.63	[-10.51, 3.24]
4_A	Doesnt_have_CBT	-11.38	[-14.75, -8.00]
4_A	Has_CBT	-18.27	[-23.16, -13.38]
4_B	Doesnt_have_HA	-10.84	[-16.53, -5.15]
4_B	Has_HA	-14.08	[-19.28, -8.88]
4_C	Doesnt_have_SC	-13.06	[-16.46, -9.66]
4_C	Has_SC	-14.76	[-19.69, -9.82]
4_D	Doesnt_have_ST	-16.19	[-20.08, -12.31]
4_D	Has_ST	-10.86	[-14.86, -6.86]
5	Brain	-16.74	[-21.73, -11.75]
5	Brain_and_Ear	-15.30	[-20.54, -10.06]
5	Ear	-9.98	[-14.37, -5.59]

44. Table S32: Per protocol (N = 185) Primary outcome (THI) at Final Visit

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-15.49	[-20.31, -10.68]
1	Single	-12.47	[-16.54, -8.40]
2	CBT	-19.05	[-27.26, -10.83]
2	CBT + HA	-10.00	[-31.74, 11.74]
2	CBT + SC	-22.75	[-36.06, -9.44]
2	CBT + ST	-18.29	[-28.35, -8.22]
2	НА	-17.48	[-24.73, -10.23]
2	HA + SC	-15.00	[-41.63, 11.63]
2	HA + ST	-9.64	[-20.99, 1.72]
2	SC	-10.38	[-19.79, -0.96]
2	SC + ST	-14.84	[-22.26, -7.41]
2	ST	-3.07	[-10.55, 4.40]
3_A	Combi_CBT	-18.72	[-26.52, -10.92]
3_A	Single_CBT	-19.05	[-27.56, -10.53]
3_B	Combi_HA	-10.38	[-19.03, -1.72]
3_B	Single_HA	-17.48	[-24.15, -10.82]
3_C	Combi_SC	-16.62	[-22.91, -10.34]
3_C	Single_SC	-10.38	[-19.76, -0.99]
3_D	Combi_ST	-14.66	[-20.15, -9.16]
3_D	Single_ST	-3.05	[-10.82, 4.72]
4_A	Doesnt_have_CBT	-11.52	[-15.20, -7.84]
4_A	Has_CBT	-18.87	[-24.49, -13.25]
4_B	Doesnt_have_HA	-11.03	[-17.36, -4.71]
4_B	Has_HA	-14.84	[-20.60, -9.07]
4_C	Doesnt_have_SC	-13.22	[-17.04, -9.41]
4_C	Has_SC	-14.73	[-20.07, -9.38]
4_D	Doesnt_have_ST	-16.62	[-20.97, -12.28]
4_D	Has_ST	-10.81	[-15.19, -6.44]
5	Brain	-16.62	[-22.33, -10.91]
5	Brain_and_Ear	-15.63	[-21.36, -9.90]
5	Ear	-10.32	[-15.14, -5.51]

45. Table S33: Per Protocol 2 (N = 155) Primary Outcome (THI) at Final Visit

Note. Per protocol 2: Additional exclusion of patients where time frame between baseline and final visit exceeded 18 weeks;

Objective	Contrast	Change_from_baseline	95% CI
1	Combination	-15.10	[-17.96, -12.24]
1	Single	-11.53	[-14.34, -8.72]
2	CBT	-18.12	[-24.10, -12.14]
2	CBT + HA	-16.00	[-27.17, -4.82]
2	CBT + SC	-19.17	[-25.55, -12.79]
2	CBT + ST	-14.02	[-19.96, -8.08]
2	НА	-14.50	[-19.74, -9.27]
2	HA + SC	-20.67	[-29.92, -11.42]
2	HA + ST	-12.92	[-20.59, -5.25]
2	SC	-11.66	[-17.35, -5.97]
2	SC + ST	-12.48	[-17.77, -7.19]
2	ST	-3.03	[-8.39, 2.33]
3_A	Combi_CBT	-16.36	[-20.49, -12.23]
3_A	Single_CBT	-18.31	[-24.41, -12.21]
3_B	Combi_HA	-15.98	[-20.92, -11.04]
3_B	Single_HA	-14.54	[-19.50, -9.58]
3_C	Combi_SC	-16.02	[-19.74, -12.30]
3_C	Single_SC	-11.66	[-17.35, -5.96]
3_D	Combi_ST	-13.05	[-16.66, -9.44]
3_D	Single_ST	-3.01	[-8.52, 2.51]
4_A	Doesnt_have_CBT	-11.40	[-13.90, -9.00]
4_A	Has_CBT	-16.90	[-20.30, -13.50]
4_B	Doesnt_have_HA	-11.09	[-15.19, -7.00]
4_B	Has_HA	-15.27	[-18.92, -11.61]
4_C	Doesnt_have_SC	-12.31	[-14.91, -9.71]
4_C	Has_SC	-14.70	[-17.87, -11.54]
4_D	Doesnt_have_ST	-15.97	[-18.68, -13.27]
4_D	Has_ST	-10.06	[-13.02, -7.09]
5	Brain	-16.00	[-19.49, -12.50]
5	Brain_and_Ear	-14.43	[-17.92, -10.94]
5	Ear	-9.69	[-13.09, -6.29]

46. Table S34: Sensitivity Analysis - Primary outcome (THI) at Final Visit

Note. Sensitivity analysis for the primary outcome was performed without imputation of the primary outcome. Objective 1: Single vs. Combination (all treatments); Objective 2: All treatments against each other; Objective 3: Single vs. Combination (separately); Objective 4: Treatments with vs. treatments without; Objective 5: Ear-mediated vs. brain-mediated vs. ear- and brain-mediated treatments.

47. References

Probst, T., Pryss, R. C., Langguth, B., Spiliopoulou, M., Landgrebe, M., Vesala, M., ... & Schlee, W. (2017). Outpatient tinnitus clinic, self-help web platform, or mobile application to recruit tinnitus study samples?. *Frontiers in aging neuroscience*, *9*, 113.